Randall Millikan, PhD, MD | Authors


Docetaxel in the Management of Advanced or Metastatic Urothelial Tract Cancer

June 01, 2002

Phase II studies of single-agent docetaxel (Taxotere) yielded promising results in advanced or metastatic transitional cell carcinoma (TCC) of the urothelium. Antitumor responses have been demonstrated in previously treated and chemotherapy-naive TCC patients, as well as in a subgroup of patients with renal impairment unable to receive traditional cisplatin-based regimens.